Home › NCT07730554
A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants
RecruitingPhase 2
A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adults
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Participant must have moderate (Grade 2) or severe (Grade 3) forehead lines (FHL) at maximum eyebrow elevation as assessed by the subject and investigator using Forehead Lines Severity Scale (FHLSS) at Screening visit and Baseline Day 1 visit. * Participant must have moderate (Grade 2) or severe (Grade 3) glabellar lines (GL) at maximum frown as assessed by the subject and investigator using Allergan Glabellar Lines Severity Scale (AGLSS) at Screening visit and Baseline Day 1 visit. * Sufficient visual acuity without the use of eyeglasses (contact lens use is acceptable) to accurately assess their FHL and GL in investigator's opinion. Exclusion Criteria: * Clinically relevant or significant ECG abnormalities. * Active infection or dermatological condition at any of the treatment injection sites.
About the study
The objective of this study is to evaluate the safety and efficacy of AGN-151586 for the treatment of moderate to severe forehead lines (FHL) in adult participants.
What is being tested
- AGN-151586 (drug)
Sponsor: AbbVie · Participants: 80 · Started: Jul 22, 2026
Contact the study team
- ABBVIE CALL CENTER · Phone: 844-663-3742
Official record on ClinicalTrials.gov — NCT07730554
Locations in the U.S.
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.